GlobeNewswire

Z-Wave Alliance Dominates Building Automation Space at Light + Building 2018

Dela

https://editorial.globenewswire.com/ResourceLibrary/ResourceLibrary/GetDynamicThumbnailContentContent/?resourceId=8b62e061-259d-48dc-aa84-20c72527daf8&maxHeight=150&maxWidth=150

Exhibitors introduce new products and demonstrate interoperability and collaboration in international Z-Wave smart building and IoT ecosystem

FRANKFURT, Germany, March 16, 2018 (GLOBE NEWSWIRE) -- Light + Building 2018 - Hall 9.1, Booth E46 - The Z-Wave Alliance, a global membership organization dedicated to advancing the popular Z-Wave wireless smart home protocol, will host the Z-Wave Pavilion at Light + Building from March 18 - 23, 2018. The Alliance is also demonstrating their award-winning installation toolkit to make installation and testing of a Z-Wave smart home mesh network even easier for the pro installer community.

The Z-Wave Pavilion will be on display at the show featuring the latest in European home and building automation and connected lighting products. Z-Wave Alliance members will demonstrate smart home lighting, thermostats, switches, air quality monitors and more. Support for the Z-Wave protocol has never been stronger - the Z-Wave Alliance now boasts over 700-member companies and over 2400 certified Z-Wave devices in the market, representing a growth of over 60% since 2015.

"The European smart building and lighting markets continue to grow, and we're excited to be at the forefront of the innovation and new technology making up this growth," said Mitchell Klein, executive director, Z-Wave Alliance. "We're excited to be back at the show with members who are breaking the mold of what the connected lighting and building markets look like now and will look like in the future."

Featured members in the Pavilion include:

CBCC/Swiid - Founded in 2013, French start-up CBCC will be exhibiting their Swiid Z-Wave home automation collection. Easy to use, Swiid products are uniquely designed and include innovative, user friendly functions.

Contec - Smart home solution manufacturer, Contec, will display their simple and attractive suite of Z-Wave plus switches. 

CTS - CTS will showcase their brand-new IoT smart gateway, S1, which is ideal for supporting a range of smart building applications like security, safety, comfort and more, and will also have interactive live demonstrations of their other SiMPNiC IoT solutions at work.

Fifthplay - A Belgian tech leader specializing in enriching smart homes and buildings, will demonstrate their IoT platform consisting of an online platform and gateway, as well as their other lighting and building product solutions.

Hank Electronics - Internationally-renowned manufacturer, Hank Electronics, will showcase their newly designed Smart Plug and in-line Smart Switch, as well as their Flood Sensor and Motion Sensor in the Pavilion, and will give attendees a preview of products coming in their roadmap.

MCOHome - Committed to the development of the IoT market, manufacturer MCOHome will feature their home automation product lines including power switches, thermostats, air quality monitors and customized hardware.

POPP - German smart home pioneer POPP will present new devices primarily used for central control of connected homes including the 433 expansion module, which allows for devices with the popular 433MHz radio frequency to be connected to the POPP HUB control center and integrated into scenes with Z-Wave devices. Another new product is the POPP Home Gateway, a Z-Wave compact camera and gateway combination.

Sorel - Sorel will be presenting their °CALEON Z-Wave Smart Thermostat. The elegantly designed °CALEON features a capacitive TFT touch panel for comfortable remote control and optimized heating and cooling comfort.

Z-Wave Alliance member and leading European distributor of Z-Wave supported smart home devices, Z-Wave Europe, will host leading manufacturers in their Pavilion, located in Hall 9.1, Booth C50 including: Aeotec, Gerber Prime, Oomi (by Fantem), Philio, Schwaiger "Home4You", Star Vedia, Steinel, TechniSat, Vision Security. These manufacturers, many of which are also Alliance members, will demonstrate new products for energy monitoring, touch panels, TV control, and more.

For more information on the Z-Wave Alliance, please visit http://z-wavealliance.org. For updates from Z-Wave at Light + Building 2018, follow the Z-Wave Alliance on FacebookTwitter and LinkedIn and with the #LB18 hashtag.

About Z-Wave
Z-Wave® technology is an open internationally recognized ITU standard (G.9959). It is the leading wireless home control technology in the market today, with over 2400 certified interoperable products worldwide.  Represented by the Z-Wave Alliance, and supported by more than 700 companies around the world, the standard is a key enabler of smart living solutions for home safety and security, energy, hospitality, office and light commercial applications.

Z-Wave® is a registered trademark of Sigma Designs. Inc. (NASDAQ SIGM) and its subsidiaries in the United States and other countries.

About the Z-Wave Alliance
Formed in January 2005, the Z-Wave Alliance is a consortium of leading companies in the home technology space dedicated to solidifying Z-Wave as the standard for wireless home control products. The principal members include: ADT, Alarm.com, ASSA ABLOY, FIBARO, Huawei, Ingersoll Rand Nexia Intelligence, Jasco Products, Leedarson, LG Uplus, Nortek Security & Control, SmartThings and Sigma Designs.  Alliance members lead the home controls market, providing leading edge products and systems that deliver increased comfort, convenience, energy conservation, safety and security.

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements about the benefits of Z-Wave Alliance membership, the benefits of the use of Z-Wave in product offerings, including the benefits of certain enhanced features of Z-Wave devices. Actual results may vary materially due to a number of factors including, but not limited to, consumer and customer acceptance of the Z-Wave Alliance (including its membership benefits), and Z-Wave technology in the relevant regions, the ability of the Z-Wave Alliance to compete with similar alliances in the industry and of the Z-Wave technology to compete with other technologies or related products in the market, if any, as well as other risks that are detailed from time to time in Z-Wave Alliance Members' reports to the Securities and Exchange Commission. Readers are cautioned not to place reliance on these forward- looking statements, which speak only as of the date hereof. We undertake no obligation to publically release or otherwise disclose the result of any revision to these forward-looking statements that may be made as a result of events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

       
Press Contact:     Caster Communications, Inc. at 401.792.7080
      Ashley Daigneault ashley@castercomm.com (401) 651-3242
      Alexandra Gil agil@castercomm.com (401) 792-7080
       
      For digital images log on to www.castercomm.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Z-Wave Alliance via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum